| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 2024 | 2014 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 1054 | 2018 |
| Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic … T Robak, A Dmoszynska, P Solal-Céligny, K Warzocha, J Loscertales, ... Journal of clinical oncology 28 (10), 1756-1765, 2010 | 621 | 2010 |
| Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia WU Knauf, T Lissichkov, A Aldaoud, A Liberati, J Loscertales, R Herbrecht, ... Journal of clinical oncology 27 (26), 4378-4384, 2009 | 614 | 2009 |
| Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 516 | 2019 |
| Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill, QA Hill, B Jilma, ... Blood reviews 41, 100648, 2020 | 496 | 2020 |
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label … P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ... The Lancet 385 (9980), 1873-1883, 2015 | 428 | 2015 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 389 | 2018 |
| Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study V Goede, K Fischer, A Engelke, R Schlag, S Lepretre, LFC Montero, ... Leukemia 29 (7), 1602-1604, 2015 | 334 | 2015 |
| Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases L Pagano, P Ricci, A Tonso, A Nosari, L Cudillo, M Montillo, A Cenacchi, ... British journal of haematology 99 (2), 331-336, 1997 | 299 | 1997 |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 … AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ... The Lancet Oncology 18 (3), 297-311, 2017 | 279 | 2017 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91, 2018 | 278 | 2018 |
| Mucormycosis in hematologic malignancies: an emerging fungal infection A Nosari, P Oreste, M Montillo, G Carrafiello, M Draisci, G Muti, A Molteni, ... Haematologica 85 (10), 1068-1071, 2000 | 275 | 2000 |
| Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ... Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015 | 271 | 2015 |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ... Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019 | 263 | 2019 |
| Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ... Journal of Clinical Oncology 38 (34), 4042-4054, 2020 | 236 | 2020 |
| Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies M Montillo, T Hamblin, M Hallek, E Montserrat, E Morra haematologica 90 (3), 391-399, 2005 | 227 | 2005 |
| Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program DL Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ... haematologica 86 (8), 862-870, 2001 | 217 | 2001 |
| Fludarabine, cytarabine, and G‐CSF (FLAG) for the treatment of poor risk acute myeloid leukemia M Montillo, S Mirto, MC Petti, R Latagliata, S Magrin, A Pinto, V Zagonel, ... American journal of hematology 58 (2), 105-109, 1998 | 199 | 1998 |
| Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia M Montillo, A Tedeschi, S Miqueleiz, S Veronese, R Cairoli, L Intropido, ... Journal of clinical oncology 24 (15), 2337-2342, 2006 | 192 | 2006 |
